Dataset: Reversal of Atopic Dermatitis with Narrow-Band UVB Phototherapy and Biomarkers for Therapeutic Response

Background: Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly Th2/“T22” immune activation and a...

Registered by ArrayExpress Uploader

View Dataset

Background: Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly Th2/“T22” immune activation and a defective epidermal barrier. Narrow-band UVB (NB-UVB) is considered an efficient treatment for moderate to severe AD. In psoriasis, NB-UVB has been found to suppress the Th1/Th17 immune polarization with subsequent reversal of epidermal hyperplasia. The immunomodulatory effects of this treatment are largely unknown in AD. Our study evaluates the effects of NB-UVB on immune and barrier abnormalities in AD, aiming to establish reversibility of disease and biomarkers of therapeutic response. Methods: 12 moderate-to-severe chronic AD patients received NB-UVB phototherapy 3 times weekly for up to 12 weeks. Lesional and non-lesional skin biopsies were obtained before and after treatment and evaluated by gene-expression and immunohistochemistry studies. Results: All patients had at least a 50% reduction in SCORing of AD (SCORAD) index with NB-UVB phototherapy. The Th2, T22, and Th1 immune pathways were suppressed and measures of epidermal hyperplasia and differentiation also normalized after phototherapy. The reversal of disease activity was associated with elimination of inflammatory leukocytes, Th2/“T22”-associated cytokines and chemokines, and normalized expression of barrier proteins. Conclusions: Our study shows reversal of both the epidermal defects and underlying immune activation in AD. By determining the correlation of variables with therapeutic response, we have defined a set of biomarkers of disease response that associate resolved Th2 and T22 inflammation with reversal of barrier pathology. This data supports the “inside-out” hypothesis of AD, suggesting that it is a disease primarily driven by an immune stimulus. genomic profiling of treatment effect of NB-UVB in AD in both lesional and non-lesional AD skin from 10 patients. Treatment effect , disease state analysis

Species:: human
Samples:: 35
Source:: E-GEOD-27887
Updated:: Dec.12, 2014
Registered:: Sep.15, 2014

Factors: (via ArrayExpress)

Sample	SCORAD	TISSUE	PATIENT	TIME
GSM688738	0	non-lesional skin	P7	post-treatment
GSM688739	0	lesional skin	P7	post-treatment
GSM688740	0	non-lesional skin	P1	post-treatment
GSM68874	0	lesional skin	P1	post-treatment
GSM688742	0	non-lesional skin	P10	post-treatment
GSM688743	0	lesional skin	P10	post-treatment
GSM688744	0	non-lesional skin	P2	post-treatment
GSM688745	0	lesional skin	P2	post-treatment
GSM688746	0	non-lesional skin	P4	post-treatment
GSM688747	0	lesional skin	P4	post-treatment
GSM688748	0	non-lesional skin	P6	post-treatment
GSM688749	0	lesional skin	P6	post-treatment
GSM688750	0	non-lesional skin	P5	post-treatment
GSM68875	0	lesional skin	P5	post-treatment
GSM688752	0	non-lesional skin	P8	post-treatment
GSM688753	0	lesional skin	P8	post-treatment
GSM688754	0	non-lesional skin	P3	post-treatment
GSM688755	0	lesional skin	P3	post-treatment
GSM688756	0	non-lesional skin	P7	pre-treatment
GSM688757	55	lesional skin	P7	pre-treatment
GSM688758	0	non-lesional skin	P9	pre-treatment
GSM688759	76	lesional skin	P9	pre-treatment
GSM688760	0	non-lesional skin	P1	pre-treatment
GSM68876	37	lesional skin	P1	pre-treatment
GSM688762	0	non-lesional skin	P10	pre-treatment
GSM688763	70	lesional skin	P10	pre-treatment
GSM688764	0	non-lesional skin	P2	pre-treatment
GSM688765	51	lesional skin	P2	pre-treatment
GSM688766	0	non-lesional skin	P4	pre-treatment
GSM688767	33	lesional skin	P4	pre-treatment
GSM688768	0	lesional skin	P6	pre-treatment
GSM688769	57	non-lesional skin	P5	pre-treatment
GSM688770	0	lesional skin	P8	pre-treatment
GSM68877	36	non-lesional skin	P3	pre-treatment
GSM688772	0	lesional skin	P3	pre-treatment